[1]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156-158.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Medical Information,2022,35(12):156-158.[doi:10.3969/j.issn.1006-1959.2022.12.038]
点击复制

双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年12期
页码:
156-158
栏目:
论著
出版日期:
2022-06-15

文章信息/Info

Title:
Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis
文章编号:
1006-1959（2022）12-0156-04
作者:
姜海燕
（佳木斯市中心医院感染科，黑龙江 佳木斯 154002）
Author(s):
JIANG Hai-yan
(Department of Infection,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
双歧杆菌四联活菌; 肝硬化; 肝功能; 细胞因子; 肠道菌群
Keywords:
Bifidobacterium tetravaccine; Liver cirrhosis; Liver function; Cytokines; Intestinal flora
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2022.12.038
文献标志码:
A
摘要:
目的 观察双歧杆菌四联活菌治疗肝硬化的临床疗效，并分析其对患者肝功能、细胞因子及肠道菌群的影响。方法 选取我院2020年3月-2021年3月收治的68例肝硬化患者为研究对象，采用随机数字表法分为对照组和观察组，各34例。对照组采用常规治疗，观察组在对照组基础上给予双歧杆菌四联活菌治疗，比较两组肝功能指标、血浆细胞因子水平、肠道菌群变化、血清内毒素和血氨水平以及临床不良反应发生情况。结果 两组ALT、TBIL及AST均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组TNF-α、IL-1及IL-8均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组肠球菌、大肠杆菌水平均低于治疗前，乳酸菌、双歧杆菌水平均高于治疗前，差异有统计学意义（P＜0.05），且观察组各菌群水平均优于对照组，差异有统计学意义（P＜0.05）；两组血清内毒素和血氨水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 双歧杆菌四联活菌治疗肝硬化效果确切，可促进患者肝功能恢复，降低细胞炎症因子水平，减轻血清内毒素，改善肠道菌群，且不良反应较少，安全性良好。
Abstract:
Objective To observe the clinical efficacy of bifidobacterium tetravaccine in the treatment of liver cirrhosis, and to analyze its effect on liver function, cytokines and intestinal flora.Methods A total of 68 patients with liver cirrhosis admitted to our hospital from March 2020 to March 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 34 cases in each group. The control group was treated with routine treatment, and the observation group was treated with Bifidobacterium tetravaccine on the basis of the control group. The liver function indexes, plasma cytokine levels, intestinal flora changes, serum endotoxin and blood ammonia levels and clinical adverse reactions were compared between the two groups.Results The levels of ALT, TBIL and AST in the two groups were lower than those before treatment, and those in the observation group were lower than the control group, the difference was statistically significant (P<0.05). The levels of TNF-α, IL-1 and IL-8 in the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The levels of Enterococcus and Escherichia coli in the observation group were lower than those before treatment, and the levels of lactic acid bacteria and bifidobacterium were higher than those before treatment, the difference was statistically significant (P<0.05); and the levels of each flora in the observation group were better than those in the control group, and the difference was statistically significant (P<0.05). The serum endotoxin and ammonia in the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Bifidobacterium tetravaccine is effective in the treatment of liver cirrhosis, which can promote the recovery of liver function, reduce the level of inflammatory factors, reduce serum endotoxin and improve intestinal flora, with less adverse reactions and good safety.

参考文献/References:

[1]王慧,李静,李锦绣.双歧杆菌四联活菌片对肝硬化患者肠道菌群、血浆内毒素及肝功能的影响[J].临床医学,2017,37(2):76-78.[2]王振宁.双歧杆菌四联活菌片对肝硬化腹泻的治疗价值评析[J].中国继续医学教育,2016,8(5):154-156.[3]孙娟,向进平.基于抗幽门螺杆菌的含铋四联疗法联合双歧杆菌四联活菌片治疗消化性溃疡的有效性和安全性分析[J].世界临床药物,2016,37(11):753-756．[4]江必武,张江春,杨林,等.谷氨酰胺联合双歧杆菌四联活菌对酒精性肝病并发慢性腹泻患者肠道菌群重建的疗效观察[J].中国医药,2017,12(1):72-76．[5]陆岽,王承党,刘霞.双歧杆菌与胶体果胶铋四联法治疗幽门螺杆菌感染效果分析[J].中华消化杂志,2017,37(12):848-849．[6]周萍,张志勇,王佐兵,等.双歧杆菌四联活菌片联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病34例[J].医药导报,2021,40(2):225-227.[7]邓桃枝,韩向阳,张洁,等.微生态制剂对慢性肝衰竭患者肠道微生态、免疫功能及炎症反应的影响[J].中国病原生物学杂志,2018,13(4):408-412．[8]黄耀强.肝硬化患者口服益生菌后肠道菌群变化分析[J].现代诊断与治疗,2017,28(7):1297-1299．[9]厉慧琴.乳果糖联合双歧杆菌四联活菌片对慢性重型乙型肝炎患者肠黏膜屏障功能的保护作用[J].中国微生态学杂志,2016,28(4):432-435．[10]金国贤,曲晓翰,郭庆,等.四君子汤联合肠内营养乳剂对肝硬化肝癌大鼠肝部分切除后免疫功能与营养状态的影响[J].解放军医药杂志,2016,28(3):81-84．[11]石勇明,周祖模,陈林.肝硬化患者益生菌干预效果及肠道菌群变化分析[J].中国微生态学杂志,2016,28(3):297-301.[12]张秋楠,肖英,苗瑞新,等.非酒精性脂肪性肝病患者肠道菌群变化与胰岛素抵抗指数、肿瘤坏死因子α和白细胞介素6的相关性分析[J].临床肝胆病杂志,2015,31(7):1078-1081.[13]史保生.双歧杆菌乳杆菌三联活菌片对非酒精性脂肪性肝病的改善作用[J].中国慢性病预防与控制,2017,25(5):387-390.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(12):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Medical Information,2022,35(12):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(12):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(12):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[6]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(12):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[7]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(12):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[8]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(12):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[9]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Medical Information,2019,32(12):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[10]曹 宇,何其顺,郭雅雯,等.延时扫描对肝硬化患者肝脏增强CT检查中动脉期时相的影响[J].医学信息,2020,33(01):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
　CAO Yu,HE Qi-shun,GUO Ya-wen,et al.Effect of Delayed Scanning on the Phase of the Middle Arterial Phase of Liver Enhanced CT in Patients with Cirrhosis[J].Medical Information,2020,33(12):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]

更新日期/Last Update: 1900-01-01